
Nuvectis Pharma initiates phase 1a NXP900 clinical trial
Betsy Goodfellow | September 13, 2023 | News story | Research and Development | Cancer, Nuvectis Pharma, Oncology, clinical trial
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, a novel inhibitor of the SRC/YES1 kinase family (SFK).
The study is intended to assess the drug’s safety, tolerability and pharmacokinetics in patients with advanced solid tumours.
NXP900 is a highly selective SFK inhibitor which includes low nanomolar IC50 against YES1 and SRC which, according to the company’s press release, “has demonstrated robust single agent anti-cancer activity against several solid tumour types in preclinical models.”
Ron Bentsur, co-founder, chairman and chief executive officer of Nuvectis Pharma, commented: “Advancing NXP900 into its first in human clinical trial is an important milestone for Nuvectis. We believe that NXP900’s unique mechanism of action, which completely shuts down signaling via SFK, in conjunction with its high target specificity, differentiates it from other multi-kinase inhibitors that also inhibit SFK and provide it with the potential to become the first SFK inhibitor for the treatment of solid tumors.”
Betsy Goodfellow
Related Content

SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …





